TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the ...

Tilray Brands has been struggling to grow its business of late. One stock that's at its all-time low right now is Tilray ...

Shares of Tilray Brands Inc. TLRY slid 3.28% to $0.43 Friday, on what proved to be an all-around mixed trading session for ...

Shares of Tilray Brands Inc. TLRY rallied 2.31% to $0.44 Thursday, on what proved to be an all-around positive trading ...

Once a leading marijuana stock, the Canadian cannabis company has pivoted to craft beer and is trying to prevent being ...

Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Read why I maintain my ...

Tilray Brands has been struggling to grow its business of late. The company still incurs losses and burns through cash. In the past, investors were optimistic about the company due to hopes that ...

A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.

Detailed price information for Tilray Brands Inc (TLRY-Q) from The Globe and Mail including charting and trades.